Eric Feinstein is the President and CEO of Clarapath, a Hawthorne, New York medical robotics company automating one of the last manual corners of the pathology lab: cutting and mounting tissue for diagnosis. Under his leadership Clarapath built SectionStar, an FDA-registered robotic microtomy platform, acquired the digital-pathology software firm Crosscope, forged a research collaboration with Mayo Clinic, and closed a $36M Series B in 2024. A former medical-device investor and operator with an MBA from Cornell, Feinstein frames the histology lab as a Lean Six Sigma manufacturing operation and pitches a broader vision he calls Laboratory 2.0.

Sus Clinicals, Inc. is a Cincinnati- and Chicago-based biotechnology company commercializing the Oncopig Cancer Model - a genetically engineered pig that develops human-like tumors on demand. Billed as the only FDA-cleared large animal cancer platform, the Oncopig carries KRAS and TP53 mutations found in more than half of human cancers, giving drug, device, and diagnostic developers a predictive testing ground that sits between the mouse and the human clinical trial. Alongside live animal supply, the company runs histology services and a tumor-tissue biorepository, and partners with CROs across the US and Europe.
HistoWiz is a New York-based histopathology company that turns tissue specimens into publication-quality digital slides in as little as three days. By pairing an automated, robot-driven lab with PathologyMap, a cloud platform hosting one of the world's largest preclinical pathology databases, it gives academic and biotech researchers fast, standardized histology plus AI analysis and access to board-certified pathologists - work that traditionally took weeks of slow, manual lab effort.